Risk of Statin-Induced Hypertransaminasemia

Rosanna Villani, MD, PhD; Eliano Pio Navarese, MD, PhD; Francesco Cavallone, MD; Jacek Kubica, MD, PhD; Francesco Bellanti, MD, PhD; Antonio Facciorusso, MD; Gianluigi Vendemiale, MD; Gaetano Serviddio, MD

Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Jun 2019)

Risk of Statin-Induced Hypertransaminasemia

Rosanna Villani, MD, PhD,
Eliano Pio Navarese, MD, PhD,
Francesco Cavallone, MD,
Jacek Kubica, MD, PhD,
Francesco Bellanti, MD, PhD,
Antonio Facciorusso, MD,
Gianluigi Vendemiale, MD,
Gaetano Serviddio, MD

Affiliations

Rosanna Villani, MD, PhD: C.U.R.E. (Centro per la Ricerca e la Cura delle Epatopatie), Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Italy
Eliano Pio Navarese, MD, PhD: Inova Heart and Vascular Institute, Fairfax, Virginia; Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland
Francesco Cavallone, MD: C.U.R.E. (Centro per la Ricerca e la Cura delle Epatopatie), Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Italy
Jacek Kubica, MD, PhD: Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland
Francesco Bellanti, MD, PhD: C.U.R.E. (Centro per la Ricerca e la Cura delle Epatopatie), Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Italy
Antonio Facciorusso, MD: C.U.R.E. (Centro per la Ricerca e la Cura delle Epatopatie), Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Italy
Gianluigi Vendemiale, MD: C.U.R.E. (Centro per la Ricerca e la Cura delle Epatopatie), Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Italy
Gaetano Serviddio, MD: C.U.R.E. (Centro per la Ricerca e la Cura delle Epatopatie), Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Italy; Correspondence: Address to Gaetano Serviddio, MD, C.U.R.E. (Centro per la Ricerca e la Cura delle Epatopatie), Institute of Internal Medicine, Viale Pinto 1, 71122 Foggia, Italy.

Journal volume & issue: Vol. 3, no. 2
pp. 131 – 140

Abstract

Read online

Objective: To assess the effect of statins compared with placebo on the risk of developing hypertransaminasemia. Patients and Methods: We performed a systematic review of electronic databases and included articles published between January 1, 1965, and April 10, 2017. Randomized clinical trials (RCTs) comparing statins vs placebo were included. Odds ratios (ORs) were pooled in random-effect meta-analyses according to established methods recommended by the Cochrane Collaboration. Results: Seventy-three eligible RCTs, comprising 123,051 patients, were identified. Statins associated with a significantly risk of hypertransaminasemia (OR 1.45; 95% confidence interval [CI], 1.24-1.69; P<.001). Atorvastatin showed the highest odds (OR 2.66; 95% CI, 1.74-4.06; P<.001) followed by rosuvastatin (OR 1.35; 95% CI, 1.06-1.70; P=.01) and lovastatin (OR 1.53; 95% CI, 1.03-2.28; P=.04). Pravastatin, fluvastatin, and simvastatin yielded no statistically different odds compared with placebo. Conclusions: A dose-dependent risk of developing hypertransaminasemia occurs in patients taking atorvastatin, rosuvastatin, and lovastatin.

Published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes

ISSN: 2542-4548 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Medicine (General)
Website: https://www.journals.elsevier.com/mayo-clinic-proceedings-innovations-quality-and-outcomes/

About the journal